Easmon C S, Woodford N, Ison C A
J Antimicrob Chemother. 1987 Jun;19(6):761-5. doi: 10.1093/jac/19.6.761.
We have compared the in-vitro activity of the 4-quinolone Ro 23 6240 and the oral cephalosporins Ro 15 8074 and Ro 19 5247 with that of penicillin, spectinomycin, cefuroxime, ceftriaxone, ciprofloxacin, ofloxacin and norfloxacin against 60 strains of Neisseria gonorrhoeae. MICs 90 against penicillinase producing N. gonorrhoeae (PPNG) and chromosomally-mediated resistant N. gonorrhoeae (CMRNG) respectively were: spectinomycin 16 and 16 mg/l, cefuroxime 0.12 and 1.0 mg/l, ceftriaxone 0.008 and 0.03 mg/l, Ro 15 8074 0.015 and 0.12 mg/l, Ro 19 5247 0.015 and 0.12 mg/l, Ro 23 6240 0.06 and 0.06 mg/l, ciprofloxacin 0.008 and 0.015 mg/l, ofloxacin 0.03 and 0.06 mg/l, norfloxacin 0.06 and 0.12 mg/l. The spectinomycin resistant and spectinomycin-sensitive strains did not differ. All three new agents show good activity against gonococci and warrant further clinical investigation. Ro 23 6240 in common with the other 4-quinolones appears to be as active against gonococcal strains exhibiting non-enzymic chromosomal resistance to penicillin as against PPNG and penicillin-sensitive isolates.
我们比较了4-喹诺酮Ro 23 6240、口服头孢菌素Ro 15 8074和Ro 19 5247与青霉素、壮观霉素、头孢呋辛、头孢曲松、环丙沙星、氧氟沙星和诺氟沙星对60株淋病奈瑟菌的体外活性。对产青霉素酶淋病奈瑟菌(PPNG)和染色体介导耐药淋病奈瑟菌(CMRNG)的90%抑菌浓度(MICs90)分别为:壮观霉素16和16mg/L,头孢呋辛0.12和1.0mg/L,头孢曲松0.008和0.03mg/L,Ro 15 8074 0.015和0.12mg/L,Ro 19 5247 0.015和0.12mg/L,Ro 23 6240 0.06和0.06mg/L,环丙沙星0.008和0.015mg/L,氧氟沙星0.03和0.06mg/L,诺氟沙星0.06和0.12mg/L。对壮观霉素耐药和敏感的菌株无差异。所有三种新药对淋球菌均显示出良好活性,值得进一步临床研究。Ro 23 6240与其他4-喹诺酮类药物一样,对表现出对青霉素非酶染色体耐药的淋球菌菌株的活性似乎与对PPNG和青霉素敏感菌株的活性相同。